Citadel Advisors
LEGN icon

Citadel Advisors’s Legend Biotech LEGN Stock Holding History

Citadel Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
65,200
+1,700
+3% +$32.4K ﹤0.01% 7282
2025
Q4 		$1.38M Buy
63,500
+26,500
+72% +$759K ﹤0.01% 6698
2025
Q3 		$1.21M Sell
37,000
-6,700
-15% -$247K ﹤0.01% 7132
2025
Q2 		$1.55M Buy
43,700
+15,600
+56% +$506K ﹤0.01% 6193
2025
Q1 		$953K Sell
28,100
-2,700
-9% -$96.8K ﹤0.01% 7061
2024
Q4 		$1M Buy
30,800
+1,500
+5% +$62.1K ﹤0.01% 7012
2024
Q3 		$1.43M Buy
29,300
+7,300
+33% +$389K ﹤0.01% 6159
2024
Q2 		$974K Sell
22,000
-75,700
-77% -$3.49M ﹤0.01% 6627
2024
Q1 		$5.48M Buy
97,700
+48,700
+99% +$2.94M ﹤0.01% 3807
2023
Q4 		$2.95M Buy
49,000
+41,300
+536% +$2.62M ﹤0.01% 4675
2023
Q3 		$517K Sell
7,700
-500
-6% -$34.7K ﹤0.01% 7999
2023
Q2 		$566K Sell
8,200
-16,900
-67% -$1.1M ﹤0.01% 7678
2023
Q1 		$1.21M Sell
25,100
-21,900
-47% -$1.07M ﹤0.01% 6375
2022
Q4 		$2.35M Sell
47,000
-5,200
-10% -$252K ﹤0.01% 5181
2022
Q3 		$2.13M Sell
52,200
-27,800
-35% -$1.3M ﹤0.01% 5473
2022
Q2 		$4.4M Buy
80,000
+47,400
+145% +$2M ﹤0.01% 4054
2022
Q1 		$1.19M Buy
32,600
+17,500
+116% +$691K ﹤0.01% 7318
2021
Q4 		$704K Buy
15,100
+11,000
+268% +$558K ﹤0.01% 8829
2021
Q3 		$207K Sell
4,100
-17,300
-81% -$720K ﹤0.01% 11917
2021
Q2 		$878K Buy
21,400
+12,500
+140% +$425K ﹤0.01% 8687
2021
Q1 		$258K Buy
+8,900
New +$243K ﹤0.01% 11172

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors's LEGN Position: Q1 2026 in Review

Citadel Advisors increased its Legend Biotech (LEGN) stake by 190% in Q1 2026, buying an estimated $6.46M and bringing the position to 516,980 shares worth $9.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3351.

Citadel Advisors first reported a position in LEGN in Q2 2020 and has held it in 24 quarters since. The position peaked at $94.5M in Q4 2024. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Citadel Advisors held 516,980 shares of Legend Biotech worth $9.35M as of Q1 2026.
  • Citadel Advisors bought 338,940 Legend Biotech shares in Q1 2026, an estimated $6.46M.
  • Legend Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3351 holding.
  • Citadel Advisors first reported a position in Legend Biotech in Q2 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Legend Biotech position peaked at $94.5M in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.